March 17, 2022 - March 22, 2022

Evoq Remedies IPO Review & Recommendations

Dilip Davda recommend to "Avoid" the IPO.

Evoq Remedies IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	0	0	0	1	0
%	0.00	0.00	0.00	100.00	0.00

Evoq Remedies IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Dilip Davda	Avoid

Evoq Remedies IPO Review by Dilip Davda (Avoid)

[Dilip Davda] The company has posted a lacklustre performance so far. The sudden boost in bottom lines since FY21 onwards appears window dressing to pave the way for fancy pricing of this IPO. The sustainability of such performance going forward is a major concern. Based on its financial parameters, the issue is aggressively priced. It is operating on third party deals only and has no assets. Considering all these, there is no harm in ignoring this highly-priced IPO. Read detail review...

Evoq Remedies IPO Review by Members

Evoq Remedies IPO Reviews, analysis and views by popular members. Read Evoq Remedies Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Evoq Remedies IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid

Member	Review
No recommendation found. Be the first to post the recommendation.

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.